282 related articles for article (PubMed ID: 35599187)
1. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
[TBL] [Abstract][Full Text] [Related]
3. Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions.
Necchi A; Nicolai N; Alessi A; Miceli R; Giannatempo P; Raggi D; Tana S; Serafini G; Padovano B; Mariani L; Crippa F; Salvioni R
Clin Genitourin Cancer; 2016 Jun; 14(3):249-54. PubMed ID: 26433626
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
[TBL] [Abstract][Full Text] [Related]
5. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
6. Can we rely on PET in the follow-up of advanced seminoma patients?
Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
[TBL] [Abstract][Full Text] [Related]
7. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206
[TBL] [Abstract][Full Text] [Related]
9. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of carboplatin AUC-10 guided by positron emission tomography-defined metabolic response in metastatic seminoma.
Shamash J; Syed R; Sarker SJ; Sarwar N; Sharma A; Mutsvangwa K; Coetzee C; Wilson P; Rustin GJ
Eur J Cancer; 2019 Jul; 115():128-135. PubMed ID: 31136925
[TBL] [Abstract][Full Text] [Related]
11. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
12. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
15. PET imaging in testicular tumours.
Calabrò D; Telo S; Ambrosini V
Curr Opin Urol; 2020 Sep; 30(5):665-671. PubMed ID: 32732623
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
Müller J; Schrader AJ; Jentzmik F; Schrader M
Urologe A; 2011 Mar; 50(3):322-7. PubMed ID: 21161157
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
[TBL] [Abstract][Full Text] [Related]
18. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
19. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
20. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
